Physician profile
Feraydoon Kohan
NPI 1831134311
$7,740.23
in general payments reported to CMS, 2019-2025
31 companies · $1,099 in 2025
The $1,099 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,247 · 2020: $608 · 2021: $1,066 · 2022: $1,038 · 2023: $1,240 · 2024: $1,442 · 2025: $1,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,781.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $984.04 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $931.75 | 2019-2025 | Jardiance |
| Abbott Laboratories | $766.25 | 2019-2025 | Jot Dx, Gallant, Aveir |
| Merck Sharp & Dohme LLC | $734.29 | 2021-2025 | Verquvo, Capvaxive |
| Astrazeneca Pharmaceuticals Lp | $616.42 | 2019-2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $583.00 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $518.02 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $436.52 | 2019-2025 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $312.95 | 2020-2025 | Lifevest |
| Amarin Pharma, INC. | $236.22 | 2019-2022 | |
| Pfizer INC. | $206.53 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $205.83 | 2024-2025 | |
| Heartflow, INC. | $164.11 | 2025 | |
| Azurity Pharmaceuticals, INC. | $160.62 | 2023-2024 | Edarbyclor, Edarbyclor, Edarbi |
| Esperion Therapeutics, INC. | $142.08 | 2020-2025 | Nexletol |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $112.02 | 2019-2022 | |
| Boston Scientific Corporation | $106.53 | 2019-2021 | |
| Amryt Pharma Holdings Ltd | $105.55 | 2021-2023 | Juxtapid |
| Lexicon Pharmaceuticals, INC. | $83.42 | 2023-2024 | Inpefa |
| Althera Pharmaceuticals LLC | $67.00 | 2021-2022 | |
| Scpharmaceuticals INC. | $62.81 | 2023-2025 | |
| Cvrx, INC. | $40.64 | 2024 | Barostim Neo System |
| Kiniksa Pharmaceuticals International, Plc | $32.87 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $25.18 | 2019 | |
| Edwards Lifesciences Corporation | $20.50 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Actelion Pharmaceuticals US, INC. | $16.04 | 2025 | Opsynvi |
| Novo Nordisk INC | $14.68 | 2025 | Ozempic |
| Gilead Sciences, INC. | $14.59 | 2019 | |
| Glaxosmithkline, LLC. | $13.99 | 2025 | Shingrix, Arexvy |
| Lundbeck LLC | $13.95 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Feraydoon Kohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.